| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||
Net loss | ||||||||
-78,708 | -82,739 | -59,606 | -43,565 | -38,824 | -37,614 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Accretion on marketable securities | ||||||||
702 | 1,020 | 0 | 0 | 0 | - | - | - | - |
Depreciation and amortization expense | ||||||||
132 | 125 | 115 | 104 | 98 | 80 | 0 | 0 | 0 |
Stock-based compensation expense | ||||||||
4,006 | 3,694 | 3,389 | 2,817 | 2,275 | 2,793 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||||
Restricted cash | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Prepaid expenses and other current assets | ||||||||
-349 | 274 | 2,374 | 843 | 447 | 630 | 0 | 0 | 0 |
Accounts payable | ||||||||
-1,923 | 3,727 | 5,765 | 3,675 | 1,661 | 1,597 | 0 | 0 | 0 |
Accrued liabilities | ||||||||
110 | 2,756 | -1,143 | -5,104 | -3,609 | -1,022 | 0 | 0 | 0 |
Funding advance | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Other liabilities | ||||||||
9 | -4 | -16 | -14 | -13 | 19 | 0 | 0 | 0 |
Net cash used in operating activities | ||||||||
-76,674 | -73,682 | -55,681 | -44,748 | -40,195 | -35,450 | 0 | 0 | 0 |
Purchases of property and equipment | ||||||||
- | 271 | 270 | 106 | 108 | 362 | 0 | 0 | 0 |
Maturities of marketable securities | ||||||||
141,500 | 141,500 | 0 | 0 | 0 | - | - | - | - |
Purchases of marketable securities | ||||||||
- | 97,103 | 0 | 0 | 0 | - | - | - | - |
Net cash provided by (used in) investing activities | ||||||||
121,254 | 44,126 | 65 | -35,521 | -135,066 | -100,716 | 0 | 0 | 0 |
Proceeds from public offering, net of issuance costs | ||||||||
- | 49,747 | 50,718 | 50,718 | 47,786 | 90,908 | 0 | 0 | 0 |
Taxes paid related to net share settlement of restricted stock units | ||||||||
0 | - | - | - | - | - | - | - | - |
Net cash (used in) provided by financing activities | ||||||||
9,632 | 56,449 | 56,465 | 50,371 | 46,821 | 89,943 | 0 | 0 | 0 |
Net increase in cash, cash equivalents and restricted cash | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Net increase (decrease) in cash and cash equivalents | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Supplemental disclosure of non-cash investing and financing activities: | ||||||||
Purchases of property and equipment included in accounts payable | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Conversion of redeemable convertible preferred stock into common stock | ||||||||
- | - | - | - | - | 81,620 | 0 | 0 | 0 |
Issuance costs associated with public offering included in accounts payable | ||||||||
- | - | - | - | 0 | - | - | - | - |